CAS 179324-69-7
:Bortezomib
Descripción:
Bortezomib es un inhibidor del proteasoma utilizado principalmente en el tratamiento del mieloma múltiple y ciertos tipos de linfoma. Es un compuesto sintético que pertenece a la clase de los derivados del ácido bórico. La fórmula química de Bortezomib es C19H25BoroN4O4, y presenta un átomo de boro que juega un papel crucial en su mecanismo de acción, que implica la inhibición del proteasoma, un complejo celular responsable de degradar proteínas ubiquitinadas. Esta inhibición conduce a la acumulación de factores pro-apoptóticos y reguladores del ciclo celular, induciendo finalmente la apoptosis en las células cancerosas. Bortezomib se administra por inyección intravenosa o subcutánea y es conocido por sus efectos secundarios, que pueden incluir neuropatía periférica, problemas gastrointestinales y toxicidades hematológicas. Su farmacocinética implica una rápida absorción y distribución, con una vida media que permite esquemas de dosificación efectivos. En general, Bortezomib representa un avance significativo en la terapia dirigida contra el cáncer, mostrando el potencial de las pequeñas moléculas en el tratamiento de malignidades hematológicas.
Fórmula:C19H25BN4O4
InChI:InChI=1S/C19H25BN4O4/c1-13(2)10-17(20(27)28)24-18(25)15(11-14-6-4-3-5-7-14)23-19(26)16-12-21-8-9-22-16/h3-9,12-13,15,17,27-28H,10-11H2,1-2H3,(H,23,26)(H,24,25)/t15-,17-/m0/s1
Clave InChI:InChIKey=GXJABQQUPOEUTA-RDJZCZTQSA-N
SMILES:[C@H](CC1=CC=CC=C1)(C(N[C@@H](CC(C)C)B(O)O)=O)NC(=O)C=2C=NC=CN2
Sinónimos:- B-[(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(2-pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic acid
- Boronic acid, B-[(1R)-3-methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(2-pyrazinylcarbonyl)amino]propyl]amino]butyl]-
- Boronic acid, [(1R)-3-methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]-
- Boronic acid, [3-methyl-1-[[1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]-, [S-(R*,S*)]-
- Bortezomib for research
- Bortizomib
- Brotezamide
- Dpba
- Ldp 341
- Mg 341
- Mln 341
- N-[(1R)-1-(dihydroxyboranyl)-3-methylbutyl]-Nalpha-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide
- N-[(1S)-1-(dihydroxyboranyl)-3-methylbutyl]-Nalpha-(pyrazin-2-ylcarbonyl)-D-phenylalaninamide
- NSC 681239
- PS 341 (pharmaceutical)
- Ps 314
- Ps 341
- Radiciol
- Velcade
- Ver más sinónimos
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
Encontrado 13 productos.
Bortezomib
CAS:Fórmula:C19H25BN4O4Pureza:>98.0%(HPLC)Forma y color:White to Almost white powder to crystalPeso molecular:384.24Bortezomib, 98%
CAS:<p>Bortezomib, 179324-69-7, is a peptidic boronic acid analog and antineoplastic agent which turns off cell signaling pathways through 26S proteasome inhibition. Learn more.</p>Fórmula:C19H25BN4O4Pureza:98%Forma y color:Powder or crystals or crystalline powder, White to off-whitePeso molecular:384.24Boronic acid, B-[(1R)-3-methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(2-pyrazinylcarbonyl)amino]propyl]amino]butyl]-
CAS:Fórmula:C19H25BN4O4Pureza:98%Forma y color:SolidPeso molecular:384.2372Bortezomib
CAS:Fórmula:C19H25BN4O4Pureza:≥ 98.0%Forma y color:White to off-white powder or solidPeso molecular:384.24Bortezomib
CAS:BortezomibFórmula:C19H25BN4O4Pureza:98% (nmr) (Typical Value in Batch COA)Forma y color: white solidPeso molecular:384.24g/molBortezomib
CAS:Bortezomib (LDP 341) is a 20S proteasome inhibitor (Ki=0.6 nM) that is reversible and selective.Fórmula:C19H25BN4O4Pureza:97.79% - >99.99%Forma y color:Yellow SolidPeso molecular:384.24Bortezomib-D8 (Major)
CAS:Producto controlado<p>Applications Labelled Bortezomib, which the first proteasome inhibitor to be approved by the US FDA for multiple myeloma, a blood cancer. A reversible inhibitor of the 26S proteasome-a barrel-shaped multiprotein particle found in the nucleus and cytosol of all eukaryotic cells.d6-3%d7-10%d8-86%<br> Not a dangerous good if item is equal to or less than 1g/ml and there is less than 100g/ml in the package<br>References Nawrocki, S.T., et al: Cancer Research, 65, 11510 (2005)<br></p>Fórmula:C19H17D8BN4O4Forma y color:Off-WhitePeso molecular:392.29Bortezomib
CAS:Producto controlado<p>Stability Hygroscopic and Moisture Sensitive<br>Applications Bortezomib is the first proteasome inhibitor to be approved by the US FDA for multiple myeloma, a blood cancer. A reversible inhibitor of the 26S proteasome-a barrel-shaped multiprotein particle found in the nucleus and cytosol of all eukaryotic cells. Targets the ubiquitin-proteasome pathway.<br> Not a dangerous good if item is equal to or less than 1g/ml and there is less than 100g/ml in the package<br>References Nawrocki, S.T., et al: Cancer Research, 65, 11510 (2005); Drahl C.: Chem. and Eng. News, 87, 41 (2009);<br></p>Fórmula:C19H25BN4O4Forma y color:White To Off-WhitePeso molecular:384.24Bortezomib - Bio-X ™
CAS:<p>Bortezomib is a selective and reversible inhibitor of the multicatalytic 26S proteasome. The inhibition of protein breakdown affects several metabolic pathways and leads to cell death. The compound is effective in treating t-cell lymphomas and multiple myeloma because it prevents the binding of myeloma cells to bone marrow stroma and inhibits osteoclast differentiation.</p>Fórmula:C19H25BN4O4Pureza:Min. 95%Forma y color:PowderPeso molecular:384.24 g/molBortezomib
CAS:<p>Selective and reversible inhibitor of the multicatalytic 26S proteasome. The inhibition of protein breakdown affects several metabolic pathways and leads to cell death. The compound is effective in treating multiple myeloma because it prevents the binding of myeloma cells to bone marrow stroma and inhibits osteoclast differentiation.</p>Fórmula:C19H25BN4O4Pureza:Min. 95%Forma y color:White PowderPeso molecular:384.24 g/mol
![Boronic acid, B-[(1R)-3-methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(2-pyrazinylcarbonyl)amino]propyl]amino]…](/_next/image/?url=https%3A%2Fstatic.cymitquimica.com%2Fproducts%2FIN%2Fthumb%2FDA0026XG.jpg&w=3840&q=75)
